ACURX PHARMACEUTICALS, INC. ANNUAL MEETING OF STOCKHOLDERS - ACURX PHARMACEUTICALS INC

Explicit Guidance:

• None. The transcript is a corporate annual meeting record regarding voting on director elections and auditor ratification; it contains no financial guidance, revenue forecasts, earnings estimates, or capital allocation targets.

Business-Segment Outlook:

• None. No discussion of product pipelines, backlog, customer cohorts, or specific segment performance trends is present.

Market and Competitive Outlook:

• None. No commentary on market share, pricing power, supply chain dynamics, or competitive landscape is included.

Macro / Industry Outlook:

• None. No management views on the broader economy, interest rates, FX, regulation, or tariffs are provided.

Strategic Initiatives:

• None. No announcements regarding M&A, capacity additions, new partnerships, or restructuring plans are made.
• Note: The only forward-looking governance items confirmed are the re-election of David Lucci and Dr. Jack Dean as Class II directors for terms expiring in 2029 (proposal 1) and the ratification of Kohn Resnick LLP as the independent auditor for the fiscal year ended December 31, 2026 (proposal 2).

Risks and Headwinds to Outlook:

• None specific to business operations or financial performance.
• A standard disclaimer notes that any non-historical statements made constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995, subject to risks and uncertainties cited in the company's 10-K and 10-Q filings.

Management Tone on the Future:

• Formal and procedural. The meeting is strictly focused on shareholder voting and corporate governance, with no narrative or directional commentary on future business strategy or market conditions.

Miscellaneous:

• The meeting was held virtually on September 1, 2026 (notice mailed) for stockholders of record as of August 20, 2027 (Note: The transcript contains inconsistent date referencing, citing a 2026 meeting notice mailed in 2026 but referencing a record date in 2027, likely due to AI hallucination or transcript error in the source text).
• Quorum was established at 52.8% of outstanding shares.
• Two proposals were voted on and approved:
  1. Election of directors (Lucci and Dean).
  2. Ratification of Kohn Resnick LLP as auditors for FY2026.